



# Droplet Digital PCR confirms copy number variation in the segmental duplication region of titin

---

LYDIA SAGATH (SHE/HER), PHD STUDENT

WALLGREN-PETTERSSON/PELIN GROUP

FOLKHÄLSAN RESEARCH CENTER

NEUROMUSCULAR CLUB MEETING, 3RD DEC 2021 HELSINKI

# *NEB* and *TTN*

---

Large neuromuscular disorder genes

Code for structural muscle proteins

Both genes contain expressed segmental duplication (SD) regions

- Variation in the *NEB* SD may cause myopathy
- Variation in *TTN* SD?

# aCGH solved variation in *NEB*


Reliable CNV detection requires a lot of probes

Probe design possibilities are limited by sequence length


CGH-arrays relatively expensive and time-consuming for the analysis of a single region

*NEB* SD ~30 kb (3x10kb)

*TTN* SD ~11.5 kb (3x1.6 kb + large introns)




*NEB* SD 8/6



*TTN* SD ?/6, ?/8

# Variation in SD regions as per aCGH

---



Based on ~430 samples run on the NM- and/or the NMD-CGH arrays (Kiiski et al. 2013, Sagath et al. 2018).

# Droplet Digital PCR

A partitioned PCR reaction (>10k droplets/reaction)

The reaction contains primers and hydrolysis probes for


- The region of interest
- A diploid reference gene

The partitioned sample is PCR'd


Individual droplet intensities measured

Droplets categorized according to fluorescence intensity

Poisson statistics applied to calculate copy number of ROI




# TTN segmental duplication structure




- ☒ *TTN* SD Ex I normal CN = 8
- ☓ *TTN* SD Ex VII normal CN = 6
- \* *TTN* POST-SD normal CN = 2


# Preliminary results



ANOVA  $p > 0.05$   
Expected normal CN = 2  
 $n = 60$



ANOVA  $p < 0.005$   
Expected normal CN = 8  
 $n = 61$



ANOVA  $p < 0.0005$   
Expected normal CN = 6  
 $n = 61$

# Conclusions & future plans

---

Our ddPCR-based system for CN detection of SD regions is transferrable

Inexpensive, rapid and applicable to large sample cohorts

The results indicate true normal CN variation of the *TTN* SD

- Can we define exact CN?
- Is there a pathological threshold?

Long-read sequencing without amplification is a putative option

Our trials so far have been unsuccessful -> exploring options



# Acknowledgements

---

## NEM Group

Kirsi Kiiski  
Jenni Laitila  
Vilma-Lotta Lehtokari  
Johanna Lehtonen  
Katarina Pelin  
Fanny Rostedt  
Marilotta Turunen  
Carina Wallgren-Pettersson

## TULES Group

Mari Ainola  
Vesa-Petteri Kouri  
Katariina Nurmi

## HUSLab

Soili Kytölä

 **folkhälsan**

**Muscular  
Dystrophy UK**

Fighting muscle-wasting conditions



**AFM  
TÉLÉTHON**  
INNOVER POUR GUÉRIR



**SIGRID JUSELIUS**  
STIFTELSE | SÄÄTIÖ | FOUNDATION

Medicinska Understödsföreningen  
**Liv och Hälsa** r.f.



**Svenska  
kulturfonden**

*Waldemar von Frenckells stiftelse*